Pharmidex Holdings Limited

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

Page 1

Page 2

Balance Sheet

As At 31 December 2024

Balance Sheet

Registered number: 07881789

		2024		2023
	Notes	£	£	£	£
FIXED ASSETS
Investments	4		2,861,618		1,684,863

			2,861,618		1,684,863
TOTAL ASSETS LESS CURRENT LIABILITIES			2,861,618		1,684,863

Creditors: Amounts Falling Due After More Than One Year	5		(2,358,457 )		(1,181,702 )

NET ASSETS			503,161		503,161

CAPITAL AND RESERVES
Called up share capital	6		143,777		143,777
Share premium account			359,384		359,384

SHAREHOLDERS' FUNDS			503,161		503,161

For the year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Professor Mohammad Alavijeh

Director

4 August 2025

The notes on page 3 form part of these financial statements.

Page 2

Page 3

Pharmidex Holdings Limited

Notes to the Financial Statements

For The Year Ended 31 December 2024

Notes to the Financial Statements

1. General Information

Pharmidex Holdings Limited is a private company, limited by shares, incorporated in England & Wales, registered number 07881789 . The registered office is 167-169 Great Portland Street, Fifth Floor, London, W1W 5PF.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.

2.3. Borrowings

Borrowings are recorded at fair value, net of transaction costs. Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

3. Average Number of Employees

Average number of employees, including directors, during the year was: NIL (2023: NIL)

4. Investments

	Unlisted
	£
Cost or Valuation
As at 1 January 2024	1,684,863
Additions	1,176,755

As at 31 December 2024	2,861,618

Provision
As at 1 January 2024	-

As at 31 December 2024	-

Net Book Value
As at 31 December 2024	2,861,618

As at 1 January 2024	1,684,863

Unlisted investments comprise shares in group undertaking and participating interests.

5. Creditors: Amounts Falling Due After More Than One Year

	2024	2023
	£	£
Amounts owed to related parties	2,358,457	1,181,702

6. Share Capital

	2024	2023
	£	£
Allotted, Called up and fully paid	143,777	143,777

7. Related Party Transactions

Amounts owed to related parties includes borrowings secured by way of a charge over all the company assets. No interest is charged and no repayment dates have been set.

Page 3

Directors	Professor Mohammad Alavijeh
	Dr Ghassem Poormand

Secretary	Professor Mohammad Alavijeh

Company Number	07881789

Registered Office	167-169 Great Portland Street
	Fifth Floor
	London
	W1W 5PF